SynthesisFrontiers in oncology2026
Nanomedicine and the tumor immune microenvironment in cancer immunotherapy: a bibliometric and knowledge-mapping analysis.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nanomedicine can improve cancer immunotherapy by enabling tumor-selective delivery and active modulation of the tumor immune microenvironment (TIME), yet the global structure and translational trajectory of this interdisciplinary field remain unclear. Methods: The Web of Science Core Collection and Scopus were searched from inception to February 1, 2025. After deduplication and screening, 1,110 English-language articles and reviews were included. VOSviewer, CiteSpace, Bibliometrix, and Python were used to analyze publication trends, collaboration networks, journal relationships, co-citation structures, citation bursts, and keyword evolution. Non-negative matrix factorization was applied to citation-burst references to identify latent thematic structures. Results: Publication output increased sharply after 2022, and studies published during 2022-2025 accounted for 79.9% of the dataset. China led in publication volume and institutional productivity, whereas the United States showed strong citation influence. Soochow University, the Chinese Academy of Sciences, and Sichuan University were the most productive institutions. Three major themes emerged: photodynamic therapy combined with immune checkpoint blockade; tumor-microenvironment remodeling and melanoma immunotherapy; and nanomaterial-mediated immune activation involving cell death, antigen release, and adaptive antitumor responses. Temporal mapping demonstrated a shift from passive nanoparticle delivery toward active immune-regulatory nanoplatforms. Conclusion: By integrating dual-database bibliometrics, citation-burst analysis, temporal knowledge mapping, and topic modeling, this study clarifies the intellectual structure and evolution of nano-immuno-oncology. Future research should prioritize biologically predictive models, reproducible manufacturing, standardized characterization, long-term safety assessment, biomarker-guided patient selection, and clinically scalable designs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.